快速阅读 麦当劳今年迄今下跌 12%,使其收益率降至 3%,而艾伯维 (AbbVie) 的 Skyrizi 和 Rinvoq 取代了 Humira,促使管理层提高了全年指引。 Lowe 的逆向案例基于住房锁定效应,将房主困在原地,并将支出转向装修而不是搬迁。 MCD 面临 21 倍远期市盈率的利润压力,ABBV 的股东权益为负,而 LOW 需要尚未完全到来的房地产复苏。
红利贵族(Dividend Aristocrats)是标准普尔 500 指数公司中连续 25 年或以上提高派息的公司,它们仍然是进入 2026 年下半年收入投资组合的基石。其中三家公司在 7 月份表现突出:一家遭受重创的快速服务龙头企业、一家全速运转的生物制药机器,以及一家为尚未完全到来的房地产复苏定价的家居装修巨头。每个选择都提供经过验证的支付、前瞻性的论文和明确的风险权衡。
麦当劳(纽约证券交易所代码:MCD)
麦当劳(NYSE:MCD | MCD 价格预测) 目前是经典的“买入弱点”设置。 7 月 6 日星期一,该公司股价约为 275 美元,年初至今下跌超过 9%,较去年下跌超过 6%。由于表现不佳,收益率已升至 2.71%,年化股息为每股 7.26 美元。
股息记录是锚。 Alpha Vantage 数据证实了从 1999 年到 2026 年不间断的季度股息历史,最近一次从每股 1.77 美元增至 1.86 美元。几十年来,麦当劳一直在提高支出,轻松地通过了贵族标准。
在运营方面,业务正在运作。 2026 年第一季度的每股收益为 2.83 美元,预期为 2.74 美元,收入为 65.2 亿美元(同比增长 9%),全球可比销售额增长 4%。首席执行官克里斯·肯普钦斯基 (Chris Kempczinski) 表示:“麦当劳本季度交付成果。我们全球系统范围内 6% 的销售额增长表明了我们如何严格执行。”更广泛经济中的食品服务支出支持了这一格局:PCE 数据显示,食品服务在 2026 年 5 月攀升至 15,383 亿美元,较 1 月份稳步增长。
风险: 通胀成本压力、关税和激烈的快餐竞争带来的利润压力可能会限制上行空间。如果公司增长停滞,21 倍的远期市盈率并不便宜。
艾伯维(纽约证券交易所代码:ABBV)
艾伯维(纽约证券交易所股票代码:ABBV)是这三者中的动力名称。该股过去一个月上涨 14%,年初至今上涨 11%,去年同期上涨 36%。每股年化股息为 6.74 美元,收益率为 2.71%。
关于贵族标签的说明:自 2013 年 1 月 1 日从 Abbott Laboratories 分拆以来,AbbVie 的独立派息连续 12 年(2013 年至 2026 年)。算上雅培的合并血统,您将达到传统的 25 年门槛,但在独立基础上,这是一个 12 年的连续派息,使季度派息从 0.40 美元增长到1.73 美元。
该增长引擎已全面取代 Humira。 2026 年第一季度收入达到 150 亿美元(同比增长 12%),其中 Skyrizi 为 44.8 亿美元(+31%),Rinvoq 为 21.2 亿美元(+23%)。管理层将 2026 年调整后每股收益指导上调至 14.08-14.28 美元。首席执行官罗伯特·迈克尔 (Robert A. Michael) 表示,艾伯维“2026 年开局良好,第一季度业绩超出了我们的预期”。
风险: Humira 生物仿制药的侵蚀仍然残酷,2025 财年特许经营权下降了 50%,资产负债表上的股东权益为负。在最近的反弹之后,估值在追踪基础上被拉伸。
劳氏 (NYSE: LOW)
劳氏 (NYSE:LOW) 是逆势选择。 7 月 6 日星期一,该股交易价格约为 221.95 美元,尽管过去一个月上涨了近 7%,但今年迄今已下跌 10%。季度股息刚刚升至 1.25 美元,下一个除息日为 7 月 22 日。
条纹是真正的贵族材料。 Alpha Vantage 数据显示,从 1999 年到 2026 年,股息逐年持续增长,第二季度派息从 1999 年的 3 美分攀升至 2026 年的 1.20 美元。
本文的研究重点是住房锁定交易。 2026 年 5 月,现房销量年化为 417 万套,仍低于 450 万套至 550 万套的健康区间。这可以让房主留在原地并推动装修支出。家具个人消费支出从 1 月份的 5,167 亿美元增至 2026 年 5 月的 5,316 亿美元。 2027 财年第一季度的业绩显示,收入同比增长 10%,达到 230.8 亿美元,连续第四个季度实现积极业绩,在线销售额增长 16%。首席执行官马文·R·埃里森(Marvin R. Ellison)表示,“春季执行力强劲,专业、家电、在线和家庭服务领域持续保持增长势头。” 2026 财年指引要求调整后稀释后每股收益为 12.25 美元至 12.75 美元。
Quick Read McDonald's 12% year-to-date slide pushes its yield to 3%, while AbbVie's Skyrizi and Rinvoq replaced Humira and drove management to raise full-year guidance. Lowe's contrarian case rests on a housing lock-in effect trapping homeowners in place and redirecting spending toward renovation over relocation. MCD faces margin pressure at a forward P/E of 21, ABBV carries negative shareholders' equity, and LOW needs a housing recovery that hasn't fully arrived.
Dividend Aristocrats, the S&P 500 companies that have raised payouts for 25 or more consecutive years, remain the bedrock of income portfolios heading into the second half of 2026. Three of them stand out for July: a beaten-down quick-service leader, a biopharma machine firing on all cylinders, and a home improvement giant priced for a housing recovery that hasn’t fully arrived. Each pick offers a verified payout, a forward-looking thesis, and a clear risk to weigh.
McDonald’s (NYSE: MCD)
McDonald’s (NYSE:MCD | MCD Price Prediction) is the classic “buy the weakness” setup right now. Shares traded around $275 on Monday, July 6, down more than 9% year to date and more than 6% over the past year. That underperformance has pushed the yield to 2.71% on an annualized payout of $7.26 per share.
The dividend record is the anchor. Alpha Vantage data confirms an unbroken quarterly dividend history from 1999 through 2026, with the most recent bump from $1.77 to $1.86 per share. McDonald’s has raised its payout for decades, comfortably clearing the Aristocrat bar.
Operationally, the business is working. Q1 2026 delivered EPS of $2.83 vs. $2.74 expected, revenue of $6.52 billion (up 9% YoY), and global comparable sales up 4%. CEO Chris Kempczinski said “McDonald’s delivered this quarter. Our 6% global Systemwide sales growth shows how we executed with discipline.” Food services spending in the broader economy supports the setup: PCE data shows food services climbing to $1,538.3 billion in May 2026, up steadily from January.
Risk: Margin pressure from inflationary cost pressures, tariffs, and intense QSR competition could cap upside. A forward P/E of 21 isn’t cheap if comp growth stalls.
AbbVie (NYSE: ABBV)
AbbVie (NYSE:ABBV) is the momentum name in this trio. The stock is up 14% over the past month, 11% year-to-date and 36% over the trailing year. The yield sits at 2.71% on an annualized payout of $6.74 per share.
A note on the Aristocrat label: AbbVie’s standalone dividend streak runs 12 consecutive years (2013 through 2026) since its spin-off from Abbott Laboratories on January 1, 2013. Counting the combined Abbott lineage gets you to the traditional 25-year threshold, but on a standalone basis, it’s a 12-year streak that has grown the quarterly payout from $0.40 to $1.73.
The growth engine has fully replaced Humira. Q1 2026 revenue hit $15 billion (up 12% YoY), with Skyrizi at $4.48 billion (+31%) and Rinvoq at $2.12 billion (+23%). Management raised 2026 adjusted EPS guidance to $14.08-$14.28. CEO Robert A. Michael said AbbVie is “off to an excellent start in 2026, with first-quarter results exceeding our expectations.”
Risk: Humira biosimilar erosion remains brutal, with the franchise down 50% in FY25, and the balance sheet carries negative shareholders’ equity. After the recent rally, valuation is stretched on a trailing basis.
Lowe’s (NYSE: LOW)
Lowe’s (NYSE:LOW) is the contrarian pick. Shares traded around $221.95 on Monday, July 6, down 10% year-to-date despite a nearly 7% bounce over the past month. The quarterly dividend just stepped up to $1.25, with the next ex-date July 22.
The streak is real Aristocrat material. Alpha Vantage data shows consistent year-over-year dividend increases from 1999 through 2026, with the Q2 payout climbing from 3 cents in 1999 to $1.20 in 2026.
The thesis hinges on the housing lock-in trade. Existing home sales sit at 4.17 million annualized in May 2026, still below the 4.5–5.5M healthy band. That keeps homeowners in place and pushes renovation spending. Furnishings PCE has accelerated to $531.6 billion in May 2026 from $516.7 billion in January. Q1 FY2027 results showed revenue up 10% YoY to $23.08 billion, the fourth consecutive quarter of positive comps, and online sales up 16%. CEO Marvin R. Ellison cited “strong spring execution and continued momentum in Pro, Appliances, Online, and Home Services.” FY2026 guidance calls for adjusted diluted EPS of $12.25–$12.75.
Risk: Housing starts dropped 15% month-over-month in May to 1.177 million units, a warning that new construction demand is slowing. Combined with margin compression from recent acquisitions and tariff exposure, the recovery could take longer than bulls expect.
Bottom Line
These three names cover different macro lanes: McDonald’s offers value and global QSR exposure at a discount, AbbVie delivers growth-driven income momentum, and Lowe’s lets investors lean into the home improvement cycle while collecting a rising payout. For income investors building a July watchlist, the combination of yield, growth, and verified dividend track records makes each worth a closer look.
_Contact editorial@247wallst.com for any questions or corrections._
About the AuthorJoel South →
Joel South covers large-cap stocks, dividend investing, and major market trends, with a focus on earnings analysis, valuation, and turning complex data into actionable insights for investors.
He brings more than 15 years of experience as an investor and financial journalist, including 12 years at The Motley Fool, where he served as an investment analyst, Bureau Chief, and later led the Fool.com investing news desk. He has also co-hosted an investing podcast and appeared across TV and radio discussing market trends.